Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

343

Participants

Timeline

Start Date

August 17, 2017

Primary Completion Date

February 14, 2020

Study Completion Date

June 20, 2024

Conditions
Renal Cell Carcinoma
Interventions
DRUG

lenvatinib

lenvatinib capsules.

DRUG

everolimus

everolimus tablets.

Trial Locations (93)

15232

University of Pittsburgh Medical Center, Pittsburgh

28040

Hospital Clinico San Carlos, Madrid

33143

Baptist Health Medical Group Oncology, LLC - US Oncology, Miami

37920

University of Tennessee Medical Center, Knoxville

52100

Presidio Ospedaliero San Donato, Arezzo

74146

Oklahoma Cancer Specialist and Research Institute , LLC, Tulsa

76104

Texas Oncology PA - US Oncology, Fort Worth

90603

Innovative Clinical Research Institute, LLC, Whittier

91010

City of Hope National Medical Center, Duarte

96819

Optimal Research, Honolulu

Unknown

Macquarie University, Macquarie Park

Northern Cancer Institute, Saint Leonards, Saint Leonards

Adelaide Cancer Center, Kurralta Park

Sunshine Hospital, Saint Albans

Fiona Stanley Hospital, Murdoch

Masarykuv onkologicky ustav, Brno

Fakultni nemocnice Olomouc, Olomouc

Fakultni nemocnice v Motole, Prague

Nemocnice Na Bulovce, Prague

Helsingin Yliopistollinen Keskussairaala, Helsinki

Tampereen yliopistollinen sairaala, Tampere

Turun Yliopistollinen Keskussairaala, Turku

Vaasan Keskussairaala, Vaasa

Alexandra Hospital, Athens

Metropolitan hospital, Athens

University General Hospital of Patras, Pátrai

Interbalkan Medical Center of Thessaloniki, Pylaia

EUROMEDICA General Clinic of Thessaloniki, Thessaloniki

Papageorgiou General Hospital of Thessaloniki, Thessaloniki

IRCCS Istituto Nazionale dei Tumori, Milan

AORN A Cardarelli, Napoli

Leids Universitair Medisch Centrum, Leiden

Hagaziekenhuis, The Hague

MC Haaglanden, The Hague

Szpital Specjalistyczny w Brzozowie, Brzozów

Copernicus PL Sp. z o.o. Wojewodzkie Centrum Onkologii, Gdansk

NZOZ Vesalius, Krakow

SP ZOZ Szpital Uniwersytecki w Krakowie, Krakow

Centrum Onkologii Ziemi Lubelskiej, Lublin

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Opolskie Centrum Onkologii, Opole

Mrukmed. Lekarz Beata Madej-Mruk i Partner. Spolka Partnerska, Rzeszów

MAGODENT Sp. z o.o. Szpital Elblaska, Warsaw

Centro Hospitalar E Universitário de Coimbra EPE, Coimbra

Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria, Lisbon

Champalimaud Cancer Center, Lisbon

Centro Hospitalar do Porto - Hospital de Santo António, Porto

Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe, Porto

Medisprof SRL, Cluj-Napoca

Prof Dr I Chiricuta Institute of Oncology, Cluj-Napoca

Oncology Center Sfantul Nectarie, Craiova

Oncocenter Clinical Oncology, Timișoara

Altay Regional Oncology Center, Barnaul

Chelyabinsk Regional Clinical Oncology Dispensary, Chelyabinsk

Central Clinical Hospital With Polyclinic of President Administration of RF, Moscow

Moscow City Oncology Hospital #62, Moscow

Moscow Scientific Research Oncology Institute P.A. Herzen, Moscow

Federal State Institution Medical Radiology Research Center, Obninsk

Clinical Oncology Dispensary, Omsk

Regional Clinical Oncology Hospital, Yaroslavl

National Cancer Center, Goyang-si

Chonnam National University Hwasun Hospital, Jeonam

Asan Medical Center, Seoul

Samsung Medical Center, Seoul

Severance Hospital - Yonsei University Health System, Seoul

The Catholic University of Korea, Seoul Saint Mary's Hospital, Seoul

Hospital Universitario A Coruna, A Coruña

Hospital Universitario Germans Trias i Pujol, Badalona

Hospital Clinic de Barcelona, Barcelona

Hospital de la Santa Creu I Sant Pau, Barcelona

C.H. Regional Reina Sofia, Córdoba

ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet de Llobregat

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario Ramon y Cajal, Madrid

MD Anderson Cancer Center Madrid, Madrid

Hospital Universitario Son Espases, Palma de Mallorca

Clinica Universidad Navarra, Pamplona

Fundacion Instituto Valenciano de Oncologia, Valencia

China Medical University Hospital, Taichung

Taichung Veterans General Hospital, Taichung

National Taiwan University Hospital, Taipei

Taipei Veterans General Hospital, Taipei

Beatson West of Scotland Cancer Centre, Glasgow

Christie Hospital, Manchester

Mount Vernon Hospital, Northwood

Singleton Hospital, Swansea

T2N 4N2

Alberta Health Service - Tom Baker Cancer Centre, Calgary

V1Y 5L3

British Columbia Cancer Agency, Kelowna

L8V 5C2

Juravinski Cancer Centre, Hamilton

N6A 4L6

London Health Sciences Centre, London

K1H 8L6

Ottawa Hospital Cancer Centre, Ottawa

M4N 3M5

Sunnybrook Research Institute- University of Toronto, Toronto

H3T 1E2

Sir Mortimer B Davis Jewish General Hospital, Montreal

00152

Azienda Ospedaliera San Camillo Forlanini, Roma

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Eisai Inc.

INDUSTRY

NCT03173560 - Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter